Ligand Pharmaceuticals price to book ratio LGND

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 6.3×
10-year median: 2.2×
Against its 10-year history: 99th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.9× to 6.4×
Peer median: 13.2×

Ligand Pharmaceuticals' price to book ratio is 6.3× as of Oct 23, 2026.

That is above its ten-year median of 2.2×, higher than on 99% of days in the last ten years.

Over that time it ranged from 0.9× in Mar 2020 to 6.4× in Jul 2026.

The median for 10 large drugmakers of a similar size is 13.2×.

Price to book ratio over time

median 2.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.3×	3.8×	6.4×
2025	4.1×	2.3×	4.8×
2024	2.5×	1.8×	2.9×
2023	1.9×	1.3×	2.3×
2022	1.4×	1.0×	1.9×
2021	2.0×	1.4×	2.9×
2020	1.4×	0.9×	1.9×
2019	1.4×	1.0×	2.9×
2018	2.6×	2.5×	6.4×
2017	4.5×	3.9×	5.0×
2016	3.9×	3.0×	5.5×
2015	4.6×	4.2×	41.7×
2014	13.1×	9.0×	21.9×
2013	15.4×	11.0×	20.2×
2012	12.1×	9.8×	77.5×
2011	61.5×	27.6×	63.6×

Against its peers

Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
AMRXAmneal Pharmaceuticals	197×
ALKSAlkermes plc.	4.0×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
INDVIndivior Pharmaceuticals	n/m
CORTCorcept Therapeutics	13.2×
ARQTArcutis Biotherapeutics	17.8×
LQDALiquidia	19.6×
OGNOrganon	3.6×
Peer median	13.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Ligand Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.